RxDoctor Payments Data

Jeffery Copeland, MD

Hospitalist · Jonesboro, ARNPI 1245618768

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Organogenesis Inc. at 57.9% of the total. Reporting peaked in 2022 at $389 and has fallen 96.2% since, to $15 in 2025. Among hospitalist clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$863in general payments, 2019–2025

Across 22 payments — averaging $39.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$500
  • GSK$104
  • AstraZeneca$104
  • Pfizer$68
  • AbbVie$30
  • Baxter Healthcare$28
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$863100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Organogenesis Inc.8$500
GSK1$104
AstraZeneca(2 entities)3$104
Pfizer5$68
AbbVie2$30
Baxter Healthcare1$28
Vertex1$15
Boehringer Ingelheim1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$863 in reported general payments places this provider in the 95th percentile of 125 hospitalist providers in Arkansas.

See all hospitalist providers in Arkansas

Medicare billing

Part B allowed, 2024
$366,444
Medicare patients
546
Services billed
3,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$72,361
JardianceEmpagliflozin57$18,153
LinzessLinaclotide24$13,899
MyrbetriqMirabegron52$11,969
FiaspInsulin Aspart (Niacinamide)37$11,463
EntrestoSacubitril/Valsartan24$8,526
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,207
TrulicityDulaglutide11$7,471
BrilintaTicagrelor27$6,784
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,583
JanuviaSitagliptin Phosphate18$5,397
Breo ElliptaFluticasone/Vilanterol11$4,782
Divalproex Sodium24$4,516
TresibaInsulin Degludec12$4,342
Potassium Chloride198$4,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$72,361235 claims
AstraZenecaBreztri Aerosphere, Brilinta, Farxiga$104$18,46551 claims
Boehringer IngelheimJardiance$15$18,15357 claims
AbbVieLinzess$30$13,89924 claims
GSKBreo Ellipta$104$4,78211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 hospitalist providers in Arkansas.

Other hospitalist in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →